Stryker (SYK) Stock Forecast & Price Target

Q: What analysts cover Stryker?

Stryker has been rated by research analysts at Barclays , BMO Capital Markets , BTIG Research , Canaccord Genuity Group , Citigroup , Citizens Jmp , Deutsche Bank , Evercore , Jefferies Financial Group , Johnson Rice , JPMorgan Chase & Co. , Leerink Partners , Needham & Company LLC , Piper Sandler , Raymond James Financial , Robert W. Baird , Rothschild & Co Redburn , Royal Bank Of Canada , Sanford C. Bernstein , Stifel Nicolaus , TD Cowen , Truist Financial , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$312.17 -6.63 (-2.08%)

Closing price 11/12/2026 03:59 PM Eastern

Extended Trading

$315.84 +3.67 (+1.18%)

As of 05:38 AM Eastern

Compare

Stryker - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 28 Analyst Ratings

Sell
0

Hold
7

Buy
21

Based on 28 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 7 have given a hold rating, and 21 have given a buy rating for SYK.

Consensus Price Target

$342.19
9.62% Upside

According to the 28 analysts' twelve-month price targets for Stryker, the average price target is $342.19. The highest price target for SYK is $405.00, while the lowest price target for SYK is $275.00. The average price target represents a forecasted upside of 9.62% from the current price of $312.17.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYK Analyst Ratings Over Time

Type	Current Forecast 11/13/25 to 11/13/26	1 Month Ago 10/14/25 to 10/14/26	3 Months Ago 8/15/25 to 8/15/26	1 Year Ago 11/13/24 to 11/13/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	21 Buy rating(s)	21 Buy rating(s)	20 Buy rating(s)	13 Buy rating(s)
Hold	7 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$342.19	$361.64	$385.64	$434.11
Forecasted Upside	9.62% Upside	28.34% Upside	13.82% Upside	16.40% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Healthcare Companies	Broader Market
Consensus Rating Score	2.75	2.32	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	9.62% Upside	113.87% Upside	13.84% Upside
News Sentiment Rating	Positive News See Recent SYK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
11/9/2026	Piper Sandler 2 of 5 stars	Matt O'Brien 2 of 5 stars	Boost Target	Overweight	$325.00 ➝ $350.00	+7.60%
11/2/2026	Stifel Nicolaus 4 of 5 stars	Rick Wise 2 of 5 stars	Lower Target	Buy	$330.00 ➝ $325.00	+9.58%
11/2/2026	Rothschild & Co Redburn 4 of 5 stars		Lower Target		$360.00 ➝ $336.00	-0.49%
11/2/2026	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Richard Newitter Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Hold	$310.00 ➝ $305.00	+0.27%
10/30/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Joanne Wuensch Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform	$317.00 ➝ $309.00	+4.49%
10/30/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Kendall Au Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Outperform	$420.00 ➝ $375.00	+26.81%
10/30/2026	Johnson Rice Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Hold
10/30/2026	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Jayson Bedford Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform	$370.00 ➝ $323.00	+3.82%
10/30/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Joanne Wuensch Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Market Outperform
10/30/2026	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Mike Matson Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$418.00 ➝ $359.00	+15.39%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
10/30/2026	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target		$385.00 ➝ $334.00	-1.07%
10/30/2026	Deutsche Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Hold	$315.00 ➝ $275.00	-18.54%
10/30/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Robbie Marcus Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Overweight	$350.00 ➝ $340.00	+16.61%
10/30/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Mathew Blackman Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Hold	$298.00 ➝ $290.00	-0.54%
10/30/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Christopher Pasquale Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Overweight	$375.00 ➝ $365.00	+24.17%
10/30/2026	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Daniel Stauder Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Market Outperform	$400.00 ➝ $390.00	+25.36%
10/30/2026	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Ryan Zimmerman Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$316.00 ➝ $304.00	-2.29%
10/30/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Kyle Rose Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Hold	$385.00 ➝ $300.00	-3.57%
10/29/2026	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Hold (C)
10/28/2026	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target		$335.00 ➝ $355.00	+5.15%
10/9/2026	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Mike Kratky Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Outperform	$403.00 ➝ $353.00	+4.56%
10/7/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Market Perform
9/22/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Buy	$440.00 ➝ $405.00	+19.96%
9/9/2026	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lawrence Biegelsen Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Overweight	$418.00 ➝ $348.00	+26.02%
8/13/2026	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Mike Polark Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Outperform ➝ Peer Perform
8/3/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Patrick Wood Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$400.00 ➝ $382.00	+13.15%
7/14/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Neutral	$363.00 ➝ $339.00	+0.44%
7/9/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$350.00 ➝ $370.00	+12.96%
3/5/2026	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform
5/2/2025	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Jason Wittes Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$405.00 ➝ $456.00	+20.75%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:56 AM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 12, 2026. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

Stryker Co. recently expanded its board of directors by nominating Jim Davis, the Chairman, CEO, and President of Quest Diagnostics, for election effective January 1, 2027, signaling a commitment to strengthening corporate governance with high-level healthcare industry expertise.
The company demonstrated strong operational resilience by reporting 7.6% year-over-year revenue growth in its most recent quarter, achieving $6.52 billion in revenue despite a slight miss in earnings per share, indicating sustained demand for its medical technology products.
Analyst sentiment remains positive with a consensus rating of Moderate Buy and a price target of $355.04, which represents significant upside potential from the current stock price of $312.17, reflecting confidence in the company's long-term value.
Stryker Co. maintains a conservative financial profile with a debt-to-equity ratio of 0.60 and a current ratio of 2.18, providing a strong liquidity buffer and financial stability that can support continued investment in research and development.
The stock offers a dividend yield of 1.09%, providing income to investors while the company continues to operate in the essential healthcare equipment and supplies sector, which tends to be less sensitive to economic cycles than other industries.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

Stryker Co. recently broke below its 200-day moving average of $323.05, a technical indicator that often signals a shift from a long-term uptrend to a potential downtrend, raising concerns about near-term price momentum.
There is significant insider selling activity, with Director Ronda Stryker selling 550,000 shares in November 2026 and multiple other insiders reducing their positions throughout 2026, which may indicate a lack of confidence in the stock's near-term performance.
The company missed its earnings per share expectations in the most recent quarter, reporting $3.52 compared to a consensus of $3.55, and also fell short of revenue targets, suggesting potential challenges in maintaining profit margins or meeting sales forecasts.
Short interest has increased to 6,660,553 shares, representing a 16.84% month-over-month rise, indicating that a growing number of investors are betting against the stock's price appreciation in the near term.
The stock is trading at a price-to-earnings ratio of 33.24, which is relatively high compared to some peers in the healthcare sector, potentially leaving little room for error if growth slows or if the broader market becomes more risk-averse.

SYK Forecast - Frequently Asked Questions

According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $342.19, with a high forecast of $405.00 and a low forecast of $275.00.

28 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last twelve months. There are currently 7 hold ratings and 21 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SYK shares.

According to analysts, Stryker's stock has a predicted upside of 9.62% based on their 12-month stock forecasts.

Over the previous 90 days, Stryker's stock had 2 downgrades and 1 upgrade by analysts.

Stryker has been rated by research analysts at Barclays, BMO Capital Markets, BTIG Research, Canaccord Genuity Group, Citigroup, Citizens Jmp, Deutsche Bank, Evercore, Jefferies Financial Group, Johnson Rice, JPMorgan Chase & Co., Leerink Partners, Needham & Company LLC, Piper Sandler, Raymond James Financial, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, Truist Financial, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Stryker more than other "healthcare" companies. The consensus rating for Stryker is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Stryker Recommendations

MarketBeat monitors more than a dozen sources for Stryker analyst ratings, with the most recent rating issued on 11/9/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target